Advertisement
U.S. Markets closed

Protara Therapeutics, Inc. (TARA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
4.0100+0.0100 (+0.25%)
At close: 04:00PM EDT
4.0300 +0.02 (+0.50%)
After hours: 07:54PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close4.0000
Open3.9900
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range3.9500 - 4.1000
52 Week Range1.0400 - 4.9500
Volume83,563
Avg. Volume79,114
Market Cap45.85M
Beta (5Y Monthly)1.90
PE Ratio (TTM)N/A
EPS (TTM)-3.5700
Earnings DateMay 02, 2024 - May 06, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est30.60
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for TARA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Protara Therapeutics, Inc.
    Daily – Vickers Top Buyers & Sellers for 06/15/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    3 years agoArgus Research
View more
  • GlobeNewswire

    Protara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

    Preliminary results from ADVANCED-1EXP trial evaluating TARA-002 in NMIBC patients with CIS on track for 1H 2024Preliminary data from ADVANCED-2 trial evaluating TARA-002 in NMIBC patients with BCG-unresponsive CIS and BCG-naïve CIS expected in 2H 2024Cash, cash equivalents, and investments of $66M as of December 31, 2023 expected to fund operations into Q2 2025 through several key data milestones NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-

  • GlobeNewswire

    Protara Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference

    NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in a fireside chat at the TD Cowen 44th Annual Health Care Conference on Wednesday, March 6, 2024 at 9:50 am ET in Boston. A live webcast of the fireside chat can be accessed by visiting the Events and Presentations section of the Company’s website: https:

  • Simply Wall St.

    We're Keeping An Eye On Protara Therapeutics' (NASDAQ:TARA) Cash Burn Rate

    There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...